LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | WZ-4-145 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1150 | 3694 | 0.3113 | -0.1474 |
| SK-BR-3 | XMD16-144 | 10.0 | uM | LJP5 | 72 | hr | 1476 | 1086 | 3694 | 0.2941 | -0.1761 |
| SK-BR-3 | Brivanib | 10.0 | uM | LJP5 | 72 | hr | 1476 | 3133 | 3694 | 0.8483 | 0.7473 |
| SK-BR-3 | Buparlisib | 10.0 | uM | LJP5 | 72 | hr | 1476 | 856 | 3694 | 0.2319 | -0.2796 |
| SK-BR-3 | BX-912 | 10.0 | uM | LJP5 | 72 | hr | 1476 | 1552 | 3694 | 0.4202 | 0.0341 |
| SK-BR-3 | Canertinib | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1006 | 3694 | 0.2724 | -0.2121 |
| SK-BR-3 | Celastrol | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1002 | 3694 | 0.2714 | -0.2138 |
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP5 | 72 | hr | 1476 | 846 | 3694 | 0.2292 | -0.2842 |
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 732 | 3694 | 0.1983 | -0.3356 |
| SK-BR-3 | CHIR-99021 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 2245 | 3694 | 0.6079 | 0.3468 |
| SK-BR-3 | CP724714 | 10.0 | uM | LJP5 | 72 | hr | 1476 | 1297 | 3694 | 0.3512 | -0.0809 |
| SK-BR-3 | CP466722 | 10.0 | uM | LJP5 | 72 | hr | 1476 | 1885 | 3694 | 0.5103 | 0.1841 |
| SK-BR-3 | Crizotinib | 10.0 | uM | LJP5 | 72 | hr | 1476 | 1094 | 3694 | 0.2963 | -0.1723 |
| SK-BR-3 | Momelotinib | 10.0 | uM | LJP5 | 72 | hr | 1476 | 1529 | 3694 | 0.4139 | 0.0236 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP5 | 72 | hr | 1476 | 1221 | 3694 | 0.3307 | -0.1150 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP6 | 72 | hr | 1476 | 881 | 3694 | 0.2386 | -0.2685 |
| SK-BR-3 | Dovitinib | 10.0 | uM | LJP5 | 72 | hr | 1476 | 1715 | 3694 | 0.4644 | 0.1076 |
| SK-BR-3 | Enzastaurin | 10.0 | uM | LJP5 | 72 | hr | 1476 | 3209 | 3694 | 0.8687 | 0.7813 |
| SK-BR-3 | Erlotinib | 10.0 | uM | LJP5 | 72 | hr | 1476 | 1857 | 3694 | 0.5029 | 0.1718 |
| SK-BR-3 | Foretinib | 10.0 | uM | LJP5 | 72 | hr | 1476 | 1382 | 3694 | 0.3743 | -0.0424 |
| SK-BR-3 | R406 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 2765 | 3694 | 0.7485 | 0.5810 |
| SK-BR-3 | Pictilisib | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1499 | 3694 | 0.4058 | 0.0100 |
| SK-BR-3 | Gefitinib | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1677 | 3694 | 0.4542 | 0.0906 |
| SK-BR-3 | Geldanamycin | 10.0 | uM | LJP5 | 72 | hr | 1476 | 597 | 3694 | 0.1616 | -0.3968 |
| SK-BR-3 | Geldanamycin | 10.0 | uM | LJP6 | 72 | hr | 1476 | 688 | 3694 | 0.1864 | -0.3554 |